UA127788U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis involves conducting a clinical examination, study of cholesterol levels of low and high density lipoproteins, arteriography. In serum, polymorphism of the eNOS T786C gene, endothelin content, TGF- (1, PSA, IL-6, homocysteine, with homozygous 786-CC carrier, endothelin levels> 10 ng / ml, TGF- (1 <14 ng / ml, is determined). EWS> 6 mg / l, IL-6> 10 ng / l, homocysteine> 20 μmol / l diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of cholesterol levels of low and high density lipoproteins, arteriography (Okorokov A.N. Diagnostics of diseases of internal organs. - Vol. 6. - P. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that along with the study of low and high-density lipoprotein cholesterol levels, arteriography in the patient's blood serum determines the polymorphism of the nitric oxide synthase gene (eMO5 1786C), the content of endothelin, transforming growth factor beta 1 (TGF-VI), C-reactive protein (SRP), interleukin b (IL-b), homocysteine. With homozygous carrier 786-SS, levels of endothelin 210 ng/ml, TFR-B1 "14 ng/ml, SRP 26 mg/l, IL-b6 "10 ng/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

Application of the method

During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. In the patient's blood serum, the eMMO5 1T786C gene polymorphism is determined, and the content of endothelin, TFR-B1I, SRP, IL-b, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 786-SS, levels of endothelin 210 ng/ml, TFR-B1 "14 ng/ml, SRP 26 mg/l, IL-b6 "10 ng/l, homocysteine 220 μmol/l, the development of atherosclerosis is diagnosed.

A specific example of using the method

Patient G., 54 years old, hospitalized in the clinic with a diagnosis of rheumatoid arthritis. Examined

Low and high density lipoprotein cholesterol levels were studied. Arteriography was performed. No signs of atherosclerosis were found. A polymorphism was determined in blood serum

Ko) of the EeMO5 gene 17860. The content of endothelin, TFR-VI, SRP, IL-b, and homocysteine was determined by the immunoenzymatic method. Homozygous carrier 786-SS was established. Levels of endothelin - 17 ng/ml, TFR-D1 - 8.9 ng/ml, SRP - 12 mg/l, IL-6 - 19 ng/l, homocysteine - 29 μmol/l. The development of atherosclerosis was diagnosed. Arteriographic confirmation of the diagnosis was obtained only after 12 months.

Thus, the proposed method makes it possible to establish a diagnosis at the early stages of the development of the process.

Claims (1)

FORMULA OF A USEFUL MODEL Method of diagnosing the development of atherosclerosis, which includes conducting a clinical examination, 40 studies of low- and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by the fact that the eMmo5 T786C gene polymorphism, the content of endothelin, TGF-DI, SRP, IL-6, homocysteine are determined in the blood serum, and in the case of homozygous carrier 786-SS, levels endothelin 210 ng/ml, TFR-DI "14 ng/ml, SRP "b mg/l, IL-b6 "10 ng/l, homocysteine 220 μmol/l diagnose the development of atherosclerosis.